Home / Fact sheets / Netherlands / Cervical qualitative data

Country fact sheet: Netherlands

CERVICAL CANCER SCREENING PROGRAMME

Reporting year for qualitative data: 2016
Source of qualitative data: Other (EU Report 2017)

Organization of screening

An individual/team/institution responsible to coordinate the programme: Yes
Dedicated budget for screening programme: Yes
Documented cancer screening policy: Yes
Nature of documentation of the policy: Law
Year programme was initiated: 1970
Programme introduction was preceded by a pilot: -
Screening tests provided free of charge: Yes
Diagnostic tests provided free of charge: Yes
Treatment services provided free of charge: -

Information system and data collection

System that collects data: Individual
   • Identification of eligible population: -
   • Screening participation: -
   • Screening test results: -
   • Further assessment: -
   • Final pathology diagnosis: -
   • Cancer staging: -
   • Treatment: -
The information system exists at national or sub-national level: Individual: Unknown
Aggregated: Unknown
The information system collects data outside the programme (opportunistic screening/private sector): -
Cancer screening data is linked with population-based cancer registry (PBCR): Yes

Screening protocol

A screening protocol or guideline: -
Year of published/updated protocol: -
Target age (min-max) and screening interval [months] for each test: Cytology (30-64 years / [60 months])
Triaging test used: None
Self-collection HPV recommended: -
"Screen and treat" included in the protocol: -
Treatment modality for "screen and treat": -

Invitations for screening and further assessment

Initiatives to create population awareness by the Health Ministry/Health Authority: -
Invitations to eligible population: Yes
Source of the eligible individuals identified:
Method of invitation: Letter
Screening kit included with the invitation: No
Screen positive individuals actively contacted for further assessment: No
Individuals with a precancer or cancer diagnosis actively contacted: -

Quality Assurance (QA) of screening activities

Documented standard operating procedure/policy for QA: Yes
An individual/team/institution responsible for QA: Yes
Accreditation of lab services: -
Accreditation of pathology services: -
Documented performance indicators: Yes
Reference standards for performance indicators: -
Evaluation reports published in the last five years: Yes

Performance indicators

Reporting year for quantitative data: 2016
Source of quantitative data: Report (EU Report 2017)
Age range and regional limitation if applicable: 30-59 years
Invitation coverage (%): 96.7
Participation rate (%): 66.0
Examination coverage (%):
Completeness of data related to screening test results (%): 100
Completeness of data related to further assessment results (%): 76.1
Further assessment (Colposcopy referral) rate (%): 1.7 (all ages)
Further assessment participation rate (%): 76.1 (all ages)
Detection rate for CIN2+ (x 1000): 7.58 (all ages)
Detection rate for CIN3+ (x 1000): 4.64 (all ages)
Detection rate for invasive cancer (x 1000):
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000): 59.5 (all ages)
Positive Predictive Value for CIN3+ (x 1000): 36.5 (all ages)
Positive Predictive Value for invasive cancer (x 1000):
More quantitative data (2009/Cytology)


Check also the following factsheets: Netherlands, Breast, Colorectal